Skip to main content
TipRanks
Go Ultimate75% OFF

Milestone Pharmaceuticals (MIST) AI Stock Analysis

829 Followers
MIST

Milestone Pharmaceuticals

(NASDAQ:MIST)

Select Model
Rating:45Neutral
Price Target:$0.45â–²(21.02% Upside)
Action:reiterated
Date:11/19/26

The score is held down primarily by weak financial fundamentals (large operating losses, heavy cash burn, and negative equity) and a pronounced bearish technical setup (below all major moving averages with negative MACD). The latest earnings call provides a partial offset through improved prescription momentum and guidance for significant cost reductions that extend runway, but valuation is not supportive due to ongoing losses and no dividend yield.

Positive Factors
Revenue Growth and Gross MarginThe sharp revenue rebound and very high gross margin indicate that CARDAMYST is beginning to generate commercially attractive product economics. If growth continues, the licensing- and royalty-style profile could support strong incremental contribution as sales scale over the next several quarters.
Negative Factors
Persistent Operating Losses and Cash BurnLarge operating losses and sustained negative operating cash flow show that current commercial revenue is far below the company’s cost base. Continued funding needs may constrain strategic flexibility and require additional financing before the business can become self-sustaining.

Milestone Pharmaceuticals (MIST) vs. SPDR S&P 500 ETF (SPY)

-100%-80%-60%-40%-20%0%20%MIST-84.98%SPY+4.27%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
$46.20M
Dividend Yield
―
Average Volume (3M)
1.53M
Price to Earnings (P/E)
-0.5
Beta (1Y)
2.58
Revenue Growth
―
EPS Growth
12.79%
Country
US
Employees
38
Sector
Healthcare
Sector Strength
51
Industry
Biotechnology

Milestone Pharmaceuticals Business Overview & Revenue Model

Company Description

Milestone Pharmaceuticals Inc. is a biopharmaceutical company based in Montréal, Canada, specializing in the creation and commercialization of cardiovascular therapeutics. Their flagship product, etripamil, an innovative channel blocker, is currently...

Milestone Pharmaceuticals Earnings Call Summary

Earnings Call Date:Nov 13, 2026(Q3-2026)|% Change Since:-43.36%|Next Earnings Date:Mar 25, 2027
Earnings Call SentimentNeutral

The call reflected solid commercial and clinical progress, including 50% sequential prescription growth, expanding prescriber breadth, broader commercial coverage, improved refill trends, and an extended cash runway through the planned AFib-RVR phase III readout. However, these positives were balanced by substantial operating losses, elevated launch-related SG&A, workforce reductions, incomplete payer coverage, adoption friction, and limited near-term Medicare contribution. Overall, management was cautiously optimistic while acknowledging that prescription growth and commercial execution still need to improve.

Positive Updates

CARDAMYST Prescriptions Increased 50% in Q3
Approximately 1,800 CARDAMYST prescriptions were recorded in Q3, representing a 50% increase over the prior quarter and bringing total prescriptions since launch to approximately 3,400.

Negative Updates

Higher Operating Expenses and Net Loss
Selling, general, and administrative expense increased to $24.2 million in Q3 2026 from $7.9 million in the prior-year period, and to $67.5 million for the first nine months from $32.3 million. Net loss increased to $25.8 million, or $0.18 per share, in Q3 from $11.9 million, or $0.12 per share, while nine-month net loss increased to $80.5 million from $45.6 million.

Company Guidance

Management expects cost-efficiency measures to reduce operating expenses by approximately 30%, with the entire process completed by the first quarter of 2027 and approximately $2 million in one-time charges; extending the operating cash runway into late 2028, more than one year beyond prior guidance, and through the anticipated phase III readout of ReVeRA-301 in the second half of 2028. Management said it does not guide to numbers for prescriptions but expects shifting up in Q4, Q1 shifting down a little as out-of-pockets and insurance plans reset, potentially starting to again inflect up in Q2, and ramping up through the second half of 2027. ReVeRA-301 is sized to about 150 events over a period of about two years, with enrollment somewhere in the range of 500 to maybe even 700 patients; for symptomatic benefit, management is looking for people to reach the six and seven category at a rate of about 45% for etripamil versus 20% for placebo, with powering greater than 90% using a two-sided alpha to get to a 0.05.

Milestone Pharmaceuticals Financial Statement Overview

Summary

Despite a sharp TTM revenue rebound (~$5.3M) with very high gross margin (~92%), the company remains deeply unprofitable (EBIT about -$91.7M) with substantial ongoing cash burn (operating cash flow about -$76.1M TTM). Balance sheet risk is elevated with negative stockholders’ equity (-$6.2M) and higher debt (~$60.9M), increasing financing/dilution risk.

Income Statement

22Negative

Balance Sheet

18Very Negative

Cash Flow

20Very Negative
Financial statement breakdown
BreakdownTTMDec 2025Dec 2024Dec 2023Dec 2022Dec 2021
Income Statement
Total Revenue5.31M1.55M01.00M5.00M15.00M
Gross Profit4.88M1.43M01.00M5.00M15.00M
EBITDA-85.76M-59.45M-37.83M-57.04M-58.30M-42.49M
Net Income-97.89M-63.06M-41.52M-59.69M-58.39M-42.85M
Balance Sheet
Total Assets162.69M113.56M75.50M75.23M74.48M119.85M
Cash, Cash Equivalents and Short-Term Investments145.35M105.96M69.69M66.00M64.58M114.14M
Total Debt60.94M58.38M54.80M51.77M2.49M698.00K
Total Liabilities168.91M71.79M62.35M58.45M8.13M7.25M
Stockholders Equity-6.22M41.77M13.15M16.77M66.35M112.60M
Cash Flow
Free Cash Flow-76.16M-49.34M-28.88M-46.54M-52.74M-33.22M
Operating Cash Flow-76.12M-49.04M-28.85M-46.42M-52.47M-33.22M
Investing Cash Flow34.33M11.25M8.28M4.76M-57.12M70.00M
Financing Cash Flow138.83M85.53M32.12M47.79M3.09M5.05M

Milestone Pharmaceuticals Technical Analysis

Technical Analysis SentimentNegative
Last Price0.37

Price Trends

50DMA0.73Negative
100DMA0.95Negative
200DMA1.27Negative

Market Momentum

MACD-0.10Positive
RSI29.94Positive
STOCH11.26Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For MIST, the sentiment is Negative. The current price of 0.37 is below the 20-day moving average (MA) of 0.63, below the 50-day MA of 0.73, and below the 200-day MA of 1.27, indicating a bearish trend. The MACD of -0.10 indicates Positive momentum. The RSI at 29.94 is Positive, neither overbought nor oversold. The STOCH value of 11.26 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for MIST.

Milestone Pharmaceuticals Risk Analysis

Milestone Pharmaceuticals disclosed 72 risk factors in its most recent earnings report. Milestone Pharmaceuticals reported the most risks in the "Tech & Innovation" category.

Higher RiskSector Avg.Lower RiskFinance & CorporateTech & InnovationLegal & RegulatoryProductionAbility to SellMacro & Political
Tech & Innovation - Risks related to the company’s reliance on technology and ability to make innovative products

Latest Risks Added

3 New Risks
1.If we fail to meet all applicable requirements of Nasdaq and Nasdaq determines to delist our common shares, the delisting could adversely affect the market liquidity of our common shares and the market price of our common shares could decrease.Q3, 2026
2.Our recently implemented cost-efficiency measures intended to extend our cash runway may not have the benefits we expect.Q3, 2026
3.Greater than expected returns of CARDAMYST may exceed our reserve for returns, which would adversely affect our revenue and operating results.Q4, 2025

Milestone Pharmaceuticals Peers Comparison

Overall Rating

UnderperformOutperform
Sector (51)

Financial Indicators

MIST against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
Sector *51Neutral$7.86B-0.30-43.30%2.27%22.53%-2.21%
ANROANRO49Neutral$1.06B-10.15-41.82%――-8.20%
CRBPCRBP46Neutral$50.18M-0.32-100.96%――-10.49%
MISTMIST45Neutral$49.71M-0.49-435.92%――12.79%
ELTXELTX39Underperform$42.46M-0.79-529.69%――46.62%
AVTXAVTX38Underperform$390.31M-2.34-34.21%―-69.27%66.84%
MCRBMCRB38Underperform$13.56M-0.25-148.34%―505.41%-889.29%

* Healthcare Sector Average

Performance Comparison

0%100%MISTCRBPMCRBAVTXELTXANRODec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
MIST and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
MISTMilestone Pharmaceuticals0.37-2.00-84.35%
CRBPCorbus Pharmaceuticals Holdings2.06-9.38-81.99%
MCRBSeres Therapeutics Inc.1.24-15.73-92.69%
AVTXAvalo Therapeutics, Inc.6.76-11.24-62.44%
ELTXElicio Therapeutics, Inc1.45-7.17-83.18%
ANROAlto Neuroscience, Inc.25.3712.0790.75%

Milestone Pharmaceuticals Corporate Events

Business Operations and StrategyDelistings and Listing ChangesRegulatory Filings and ComplianceStock Split

Milestone Pharmaceuticals Faces Nasdaq Listing Compliance Challenge

Negative
Oct 28, 2026

On October 23, 2026, Milestone Pharmaceuticals Inc. disclosed that it received a notice from Nasdaq stating its common shares had closed below the $1.00 minimum bid price requirement for 30 consecutive business days, putting the company out of compli...

Business Operations and StrategyProduct-Related Announcements

Milestone Wins China Approval for Etripamil Nasal Spray

Positive
Sep 3, 2026

On September 3, 2026, Milestone Pharmaceuticals announced that China’s National Medical Products Administration approved etripamil nasal spray for treating paroxysmal supraventricular tachycardia in adults, marking the first regulatory authorization...

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Nov 19, 2026